Hodgkin lymphoma is among the most curable cancers, with the American Cancer Society estimating about 8,920 new U.S. cases and roughly 900 deaths in 2026, and overall 5-year survival near 89-95%. But the disease has a bimodal age distribution, and in its second incidence peak, ages 50 to 70, that same curability carries a different risk profile: treatment-related mortality with standard ABVD chemotherapy reaches 5-9% in patients over 60, versus about 0.3% in younger patients. Because this older-adult peak more often presents with mixed cellularity histology, EBV-positive disease, and advanced stage, precise subtype and staging documentation is central to matching treatment intensity to what each patient can tolerate.
AAVBC's Hodgkin's Lymphoma Quick Reference Guide equips primary care clinicians and care teams with a comprehensive, evidence-aligned reference covering ICD-10 C81 subtype and site coding specificity, HCC 21 RAF mapping, the PET-first diagnostic and response-adapted treatment strategy, Ann Arbor/Lugano staging, geriatric risk factors and B-symptom recognition, MEAT documentation standards, and NCCN-aligned treatment, referral, and survivorship monitoring for late cardiovascular and pulmonary toxicity. Grounded in NCCN guidance, this guide supports consistent, individualized clinical decision-making, helping care teams recognize red-flag presentations in older adults and code subtype and stage with the specificity risk adjustment requires, with the clarity and continuity that durable outcomes require.
AAVBC’s Deep-Dive series offers a comprehensive, structured analysis of Hodgkin's lymphoma — moving far beyond quick-reference essentials. These guides provide an integrated review of epidemiology, diagnostic strategy, staging, coding logic, MEAT-aligned documentation examples, treatment guidelines, review vulnerabilities, and cost-utilization considerations. The Deep-Dive combines evidence-informed clinical guidance with practical operational tools to support a deeper understanding of disease complexity and provide multidisciplinary teams with strategies to thrive within value-based frameworks.
Hodgkin lymphoma is among the most curable cancers, with the American Cancer Society estimating about 8,920 new U.S. cases and roughly 900 deaths in 2026, and overall 5-year survival near 89-95%. But the disease has a bimodal age distribution, and in its second incidence peak, ages 50 to 70, that same curability carries a different risk profile: treatment-related mortality with standard ABVD chemotherapy reaches 5-9% in patients over 60, versus about 0.3% in younger patients. Because this older-adult peak more often presents with mixed cellularity histology, EBV-positive disease, and advanced stage, precise subtype and staging documentation is central to matching treatment intensity to what each patient can tolerate.
AAVBC's Hodgkin's Lymphoma Quick Reference Guide equips primary care clinicians and care teams with a comprehensive, evidence-aligned reference covering ICD-10 C81 subtype and site coding specificity, HCC 21 RAF mapping, the PET-first diagnostic and response-adapted treatment strategy, Ann Arbor/Lugano staging, geriatric risk factors and B-symptom recognition, MEAT documentation standards, and NCCN-aligned treatment, referral, and survivorship monitoring for late cardiovascular and pulmonary toxicity. Grounded in NCCN guidance, this guide supports consistent, individualized clinical decision-making, helping care teams recognize red-flag presentations in older adults and code subtype and stage with the specificity risk adjustment requires, with the clarity and continuity that durable outcomes require.
AAVBC’s Deep-Dive series offers a comprehensive, structured analysis of Hodgkin's lymphoma — moving far beyond quick-reference essentials. These guides provide an integrated review of epidemiology, diagnostic strategy, staging, coding logic, MEAT-aligned documentation examples, treatment guidelines, review vulnerabilities, and cost-utilization considerations. The Deep-Dive combines evidence-informed clinical guidance with practical operational tools to support a deeper understanding of disease complexity and provide multidisciplinary teams with strategies to thrive within value-based frameworks.
